Colorectal Cancer Study of Austria (CORSA): A Population-Based Multicenter Study

Abstract

The COloRectal cancer Study of Austria (CORSA) is comprised more than 13,500 newly diagnosed colorectal cancer (CRC) patients, patients with high- and low-risk adenomas as well as population-based controls. The recruitment for the CORSA biobank is performed in close cooperation with the invited two-stage CRC screening project “Burgenland PREvention trial of colorectal Disease with ImmunologiCal Testing” (B-PREDICT). Annually, more than 150,000 inhabitants of the Austrian federal state Burgenland aged between 40 and 80 are invited to participate using FIT-tests as an initial screening. FIT-positive tested participants are offered a diagnostic colonoscopy and are asked to take part in CORSA, sign a written informed consent, complete questionnaires concerning dietary and lifestyle habits and provide an ethylenediaminetetraacetic acid (EDTA) blood sample as well as a stool sample. Additional CRC cases have been recruited at four hospitals in Vienna and a hospital in lower Austria. A major strength of CORSA is the population-based controls who are FIT-positive and colonoscopy-confirmed to be free of polyps and/or CRC.

Higher Plasma Creatinine Is Associated with an Increased Risk of Death in Patients with Non-Metastatic Rectal but Not Colon Cancer: Results from an International Cohort Consortium

“…MetaboCCC is a large European consortium investigating metabolic profiles across the continuum of colorectal cancer carcinogenesis [ 19 ]. The cohorts included in this study consist of: the COLON study, conducted in the Netherlands [ 20 ]; the EnCoRe study, also conducted in the Netherlands and registered under the Netherlands Trial Register with the identifier 7099 [ 21 ]; the Heidelberg site of the ColoCare Study, registered under with the identifier NCT02328677 [ 22 ]; and the Colorectal Cancer Study of Austria (CORSA) [ 23 ]. These cohorts were selected for their relevance to the research and their contribution to the comprehensive analysis conducted in this study.…”

“…For more detailed information, please refer to the previously published manuscript [ 14 ] and the study design manuscripts specific to each cohort. COLON study: a prospective cohort study conducted in the Netherlands, with recruitment commencing in 2010 [ 20 ]; EnCoRe study: an ongoing prospective cohort study [ 21 ]; ColoCare Study: an ongoing international multi-center prospective study that commenced in 2007 [ 22 ]; CORSA: an ongoing cohort study that recruits CRC patients in collaboration with the Burgenland Prevention Trial of Colorectal Disease with Immunological Testing (B-PREDICT) project since 2003 [ 23 ]. Additional recruitment takes place at four hospitals in Vienna.…”

Use of Omics Technologies for the Detection of Colorectal Cancer Biomarkers

“…Sample collection is non-invasive, the test can be performed at home, there is no sample amount limitation, and the stool effectively samples the entire length of the inner bowel wall contents (including tumour) as it passes down the gastrointestinal tract [53]. For this reason, stool samples are increasingly gaining attention in the search for new biomarkers for the early detection of CRC [54,55].…”

Using fecal immmunochemical cartridges for gut microbiome analysis within a colorectal cancer screening program

“…In the ongoing “Colorectal Cancer Study of Austria” (CORSA) participants are recruited in cooperation with the province‐wide screening project “Burgenland Prevention Trial of Colorectal Disease with Immunological Testing” (B‐PREDICT), since 2003. 9 B-PREDICT, conducted in the Austrian federal state Burgenland, is an invited two-stage screening project for individuals aged between 40 and 80 using a fecal immunochemical test (FIT) for initial screening. Participants with a positive test are offered a diagnostic colonoscopy.…”